{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-004156","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2022-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.503529+00:00","generated_at":"2026-06-26T19:43:20.238860+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Reneo Pharma reports Q4 net loss $10.6M; cash $147.7M; no Phase 2 for McArdle","bullets":["Net loss for Q4 2021 was $10.6M ($0.43 per share) vs $6.3M in Q4 2020; full year net loss $39.8M.","Cash, cash equivalents and short-term investments at Dec 31, 2021: $147.7M, sufficient into 2024.","STRIDE Phase 2b PMM study enrollment ongoing; data expected in 2023; LC-FAOD data in 2Q 2022.","REN001 in McArdle disease: no drug-related SAEs; company will not pursue Phase 2 for McArdle.","Appointed Ashley Hall as Chief Development Officer and Eric Dube to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-004156","json":"https://secwatch.observer/filing/0001558370-22-004156.json","markdown":"https://secwatch.observer/filing/0001558370-22-004156.md","text":"https://secwatch.observer/filing/0001558370-22-004156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000155837022004156/0001558370-22-004156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000155837022004156/rphm-20220323x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T19:43:20.238860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}